A blood miRNA signature associates with sporadic Creutzfeldt-Jakob disease diagnosis and rate of progression

Penny J. Norsworthy[1]; Andrew G.B. Thompson[2]; Tze H. Mok[2]; Ross W. Paterson[3]; Jonathan M. Schott[3]; John Collinge[1,2]; Simon Mead[1,2,*]; and Emmanuelle A. Viré[1]

[1]MRC Prion Unit at UCL, UCL Institute of Prion Diseases, London, UK.

[2]National Prion Clinic, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK.

[3]Dementia Research Centre, UCL Institute of Neurology, University College London, London, UK.

[*]Corresponding author: Prof. Simon Mead, MRC Prion Unit at UCL, UCL Institute of Prion Diseases, Courtauld Building, 33 Cleveland Street, London, W1W 7FF, UK. Email: s.mead@prion.ucl.ac.uk, Tel: +44 20 7679 5152

Abstract

Sporadic Creutzfeldt-Jakob disease (sCJD) presents as a rapidly progressive dementia which is usually fatal within six months. No blood tests are currently available for diagnosis or disease monitoring. Here, we profile blood microRNA (miRNA) expression in sCJD. Small RNA-sequencing of 57 sCJD patients and 50 healthy controls reveals differential expression of hsa-let-7i-5p, hsa-miR-16-5p, hsa-miR-93-5p, hsa-miR-106b-3p and hsa-let-7d-3p. Downregulation of hsa-let-7i-5p, hsa-miR-16-5p and hsa-miR-93-5p in sCJD replicates in an independent cohort using quantitative PCR, with concomitant upregulation of four of their mRNA targets. This miRNA signature discriminates patients with sCJD from Alzheimer's disease patients. Finally, longitudinal monitoring of 15 sCJD patients shows that the rate of decline in miRNA expression significantly correlates with rate of disease progression. These findings highlight novel molecular alterations in human prion disease outside the central nervous system which can provide information about diagnosis, disease progression, and improve mechanistic understanding of sCJD.

Introduction

Sporadic Creutzfeldt-Jakob disease (sCJD) is a transmissible neurodegenerative condition which typically develops in late middle age, is currently untreatable, and usually results in death within six months of symptom onset. Its characteristic pathological features are the development of spongiform change in the cerebral grey matter associated with deposition of abnormal forms of prion protein (PrP)[1]. sCJD is thought to be caused by the spontaneous formation of prions, an infectious agent comprised of multimeric assemblies of misfolded PrP[2,3]. Susceptibility to, and progression of, the disease is known to be strongly influenced by a common polymorphism at codon 129 of the prion protein gene (*PRNP*)[4,5], and at the protein level several different strains of misfolded PrP are known to exist which can influence the course of the disease[6]. Prions are highly concentrated in brain tissue at post mortem examination of sCJD, but are also detectable in peripheral tissues, with no apparent biological consequences[7-10]. Specific diagnostic tests are available including brain magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) analyses; however, no simple blood assay has been developed. Here we investigated blood microRNA (miRNA) profiles to explore whether these would disclose novel accessible biomarkers or insights into the peripheral pathobiology of the most common human prion disease.

Small non-coding RNAs, such as miRNAs, are highly conserved oligonucleotides (19-22 bases) which can inhibit translation of targeted messenger RNA (mRNA) transcripts and tag them for degradation[11]. miRNAs are powerful regulators of gene expression because one miRNA can target multiple coding genes. Due to their remarkable stability in body fluids[12], miRNAs represent attractive biomarkers and drug targets, and their dysregulation has been widely described in disease states[13-15]. Moreover, since miRNAs in blood often originate from other tissues, the study of miRNAs can provide novel insights into pathological mechanisms in inaccessible tissues such as the brain[12]. miRNAs have been extensively studied in Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD) and Amyotrophic Lateral Sclerosis (ALS)[16-19].

In prion disease, only a few studies have investigated the contribution of miRNAs to disease initiation and progression, and most of the work has focused on animal models and brain tissue, limiting

existing knowledge in humans to the end-stage of the disease[20]. Here, we profiled miRNA expression levels in whole blood by case-control study. Small RNA-sequencing (RNA-seq) identified five differentially expressed (DE) miRNAs. Using quantitative PCR (qPCR) in an independent cohort we validated and replicated the finding that hsa-let-7i-5p, hsa-mir-16-5p and hsa-mir-93-5p are downregulated in sCJD. To gain further insight into the potential use of the signature in differential diagnosis, we measured levels of these miRNAs in whole blood from patients with AD and showed that the miRNA signature in sCJD is clearly differentiated from AD. We also observed that expression of downstream mRNA targets of these miRNAs are affected in sCJD blood. Finally, by interrogating 37 longitudinal samples from a group of 15 sCJD patients we identified a significant correlation between rate of change of DE miRNA expression and rate of disease progression.

Results

Sequencing of small RNA in blood identifies five miRNAs differentially expressed between sCJD cases and healthy controls

To investigate if miRNA profiles could discriminate patients with sCJD from healthy controls, we designed a case-control study using blood from 57 sCJD cases and 50 controls (Table 1). Using next-generation sequencing, we measured expression of miRNAs in all samples. Across all sequencing runs, the mean percentage of clusters passing filter was 84.43%, and the mean percentage of bases with Q>30 was 84.80%. Across all samples, 94.71% of reads were successfully aligned to the genome, and 94.70% of these reads aligned uniquely. The mean Q score for aligned reads was 36.6. After alignment and normalization of reads, 939 unique miRNAs were detected.

110 miRNAs which passed low expression filtering were analyzed for differential expression (Supplementary Table 1). Figure 1a, and Supplementary Table 1, show that five miRNAs were found to have a statistically significant fold change (FC) of at least 1.5 between cases and controls after False Discovery Rate (FDR) correction for multiple testing. Figure 1b shows that hsa-let7i-5p (FC –2.63, adjusted $p=6.37x10^{-3}$), hsa-miR16-5p (FC –2.47, adjusted $p=6.37x10^{-3}$), hsa-miR-93-5p (FC –2.48, adjusted $p=3.7x10^{-4}$), and hsa-miR-106b-3p (FC –1.75, adjusted $p=6.37x10^{-3}$) were downregulated in sCJD compared to healthy controls, whilst levels of hsa-let-7d-3p (FC 2.00,

adjusted p=0.019) were found to be elevated in sCJD blood. Age was included as a covariate in the regression test, and none of these five miRNAs showed a significant correlation with age in controls (each p>0.01, R^2 0.01-0.12). Although the RNA we were able to obtain for a proportion of sCJD patients in our study was sub-optimal in terms of RNA Integrity Number (RIN) for mRNA analysis, miRNA is highly resistant to degradation[21], and two independent analyses of the small RNA-seq data, firstly excluding RNA samples where RIN<4, and secondly including RIN as a covariate in the statistical model, did not alter the findings reported here (Supplementary Table 2).

Unsupervised hierarchical clustering analysis using these five differentially expressed miRNAs yielded two major clusters of samples, with most healthy individuals clustering tightly together (Fig.1c). When the data was stratified based on *PRNP* codon 129 (either MM, MV, or VV) (Supplementary Fig.1); or PrP^{Sc} strain type (the prion protein disease isoform typed by the London classification, types 2 or 3, n=22), no significant differences were observed, suggesting that these factors have little or no effect on expression of these miRNAs.

In a subset of the 939 detected miRNAs with sufficient data for analysis (including those excluded from differential expression analysis by the low expression filter), expression in sCJD patients was tested for correlation with clinical parameters (age of onset, duration of disease, MRC Scale score and MRC Scale slope). No significant associations were observed after correction for multiple testing.

Signature of differentially expressed miRNAs in blood from sCJD patients is replicated in an independent cohort

Having identified a blood-based miRNA signature for sCJD, we aimed to validate and replicate these results using an independent cohort and technique. The replication cohort comprised 29 sCJD patients and 30 healthy age and sex matched control individuals (Table 1). Reverse transcription quantitative PCR (RT-qPCR) was used to measure the relative levels of expression of the five differentially expressed miRNAs. hsa-miR-484, which was not differentially expressed in the discovery study (FC 1.07, adjusted p=0.658), was also included. Having determined that levels of endogenous controls did not vary between cases and controls (Supplementary Fig.2d), we used RNU6-2, SNORD42B, SNORD95 and SNORD72 to normalise miRNA expression levels. Lower levels of hsa-let-7i-5p, hsa-miR-16-5p and hsa-miR-93-5p were found in sCJD blood, whilst hsa-miR-484 remained

unchanged as expected (Fig.2a, and Supplementary Fig.2a-c), thereby replicating the findings from the discovery study. Of the remaining two miRNAs tested, hsa-miR-106b-3p amplified poorly, while hsa-let-7d-3p was not replicated (Fig.2a, and Supplementary Fig.2a-c).

miRNA targets are dysregulated in blood from sCJD patients

Next, we hypothesized that if differential miRNA expression plays a role in the peripheral pathophysiology of sCJD, relevant mRNA targets should also be altered in sCJD blood. We identified these mRNA targets using TarBase with stringent criteria (validated using luciferase assays and/or validated by immunoprecipitation; expressed in whole blood). Using RT-qPCR we measured the expression of six transcripts reported to be under the control of hsa-let-7i-5p, hsa-miR-16-5p and hsa-miR-93-5p in the replication cohort: *CCND3*, *VEGFA*, *NAP1L1*, *ZFP36*, *CDKN1A* and *RNF44*. Figure 2b shows that blood samples from sCJD patients display higher levels of four of these transcripts in comparison to blood from controls, which is consistent with a reduction of miRNA silencing of target mRNA. Mean endogenous control Ct values showed no significant differences between control and sCJD groups (Supplementary Fig.3). Finally, to gain insight into biological processes by which these miRNAs may contribute to sCJD, we performed pathway enrichment analysis using the six targets of the Differentially Expressed (DE) miRNAs. Results presented in Supplementary Table 3 suggest that all six target genes are associated with central nervous system tissues (ophthalmic nerve, embryonic brain, amygdala, prefrontal cortex). Altogether, these results demonstrate that hsa-let-7i-5p, hsa-miR-16-5p and hsa-miR-93-5p are downregulated in sCJD blood, and concomitantly, levels of their selected mRNA targets are elevated.

Downregulation of hsa-let-7i-5p, hsa-miR-16-5p and hsa-miR-93-5p is specific to sCJD

To further investigate the relevance of this blood-based miRNA signature to sCJD we next set out to profile levels of hsa-let-7i-5p, hsa-miR-16-5p and hsa-miR-93-5p in blood collected from patients with AD. A group of 30 AD patients were matched by sex and age to the control group used for the replication analysis (Table 1). RT-qPCR data presented in Fig.3, and Supplementary Fig.4a-c, show that, in marked contrast to sCJD, hsa-let-7i-5p, hsa-miR-16-5p and hsa-miR-93-5p were upregulated in AD patients. Mean endogenous control Ct values showed no significant differences between control and AD groups (Supplementary Fig.4d). These results demonstrate that levels of hsa-let-7i-5p,

hsa-miR-16-5p and hsa-miR-93-5p in blood establish a signature which enables discrimination between healthy controls, AD, and sCJD.

Rate of decline in miRNA levels correlates with sCJD rate of progression

Finally, although there was no cross-sectional correlation between disease metrics and DE miRNAs, we asked whether the rate of decrease in miRNA expression could be related to the speed of decline observed in individual patients with sCJD. High inter-individual variation might obscure intra-individual longitudinal effects over time. To this end, bloods were collected longitudinally from fifteen individuals with sCJD (Table 1). At time of sampling, each patient's condition was assessed using the MRC Prion Disease Rating Scale, allowing for disease progression to be monitored (% loss of function per day by mixed effects regression). Levels of expression for hsa-let-7i-5p, hsa-miR-16-5p, hsa-miR-93-5p and hsa-miR-484 were quantified by RT-qPCR and values were converted into rate of expression decline (reduction in expression per day). Figure 4a-d, and Supplementary Fig.5a-d and 6a-d, shows that rate of decline in levels of hsa-let-7i-5p, hsa-miR-16-5p and hsa-miR-93-5p were all significantly positively correlated with rate of disease progression (% loss of function per day). In contrast hsa-miR-484, found to be unaltered in sCJD blood, displayed no correlation with disease progression (Fig.4a-d, and Supplementary Fig.5a-d and 6a-d).

Discussion

Sporadic Creutzfeldt-Jakob disease, the most common human prion disease and the archetypal rapidly progressive dementia, presents with neurological and/or neuropsychiatric features, and diagnosis is supported by abnormalities of brain imaging, neurophysiology or CSF analysis. Currently available blood tests do not help to distinguish sCJD from other neurodegenerative disorders. Here, for the first time, we show replicated evidence of specific dysregulation of miRNAs in the peripheral blood of sCJD patients. Using next-generation sequencing to profile miRNA expression in peripheral blood, we identified, validated, and replicated three miRNAs (hsa-let-7i-5p, hsa-miR-16-5p and hsa-miR-93-5p) whose expression is significantly lower in the blood of sCJD patients than in healthy individuals. Expression of this sCJD miRNA signature decreases as the disease progresses, and furthermore, we report that the levels of these three miRNAs distinguish patients with sCJD from

patients with AD. These findings suggest there is a peripheral blood molecular signature in sCJD that could be explored for potential future applications as a biomarker for diagnosis and progression.

Each dysregulated miRNA could plausibly have implications for the pathobiology of sCJD. hsa-miR-93-5p is a member of the miR-106b-25 miRNA cluster (comprising hsa-miR-106b, hsa-miR-93 and hsa-miR-25), located on chromosome 7 within the *MCM7* gene. Expression of both the miR-106b-25 cluster and *MCM7* (which is also downregulated in sCJD blood, Supplementary Fig.7) is regulated by the transcription factor E2F1, a cell cycle regulator which has been associated with neurotoxicity in neurodegenerative disease[22-24]. In the discovery cohort the other two members of the cluster, hsa-miR-106b-3p and hsa-miR-25-3p, were also downregulated in sCJD patients. However, expression of hsa-miR-106b-3p was too low to allow replication by qPCR, and the adjusted p value for hsa-miR-25-3p fell short of significance (p=0.09, Supplementary Table 1). Repression of this cluster has previously been shown to be required for endoplasmic reticulum (ER) stress induced apoptosis, a common feature of neurodegenerative diseases[25,26]. It is unsurprising to find that members of this cluster are dysregulated in sCJD since alterations in hsa-miR-93-5p expression have been previously linked to AD and ALS[18,27], and the prion protein gene, *PRNP,* has been identified as a potential target of hsa-miR-93-5p[28-30].

hsa-let-7i-5p has also been implicated in neurodegenerative disorders. In ALS, Liguori *et al* reported downregulation of hsa-let-7i-5p in whole blood[18]. Conversely, in AD, elevated levels of hsa-let-7i-5p were found in brain, plasma and CSF[31,32]. These findings are consistent with our observations of hsa-let-7i-5p's downregulation in sCJD blood but upregulation in AD whole blood (Fig.2a and 3). More relevant is the report that levels of hsa-let-7i-5p were found to be elevated in exosomes from neurons of prion-infected mice[33].

hsa-miR-16-5p features prominently in existing literature on miRNA and neurodegeneration, and prion disease in particular. Studies in prion-infected mice have shown a distinct temporal pattern of dysregulation of hsa-miR-16-5p as disease progresses, whereby expression is upregulated in cultured primary neurons in the pre-symptomatic phase but downregulated in the clinically established disease phase[34,35]. Our observations of downregulation of hsa-miR-16-5p in blood from patients with

clinically established sCJD concur with these findings. In humans, Llorens and colleagues reported increased levels of hsa-miR-16-5p in sCJD frontal cortex[36]. In ALS, hsa-miR-16-5p was found to be downregulated in whole blood[18], and in AD, several clinical and mechanistic studies have suggested that hsa-miR-16-5p plays a role in pathogenesis[37-39].

The question of whether dysregulated miRNAs are shared between neurodegenerative disorders is crucial because of the unmet need for the treatment of these diseases. Therefore, lifting the veil on molecular mechanisms involved in neurodegeneration could help provide evidence for better disease classification and drug design. Together with the literature, our results suggest that the same small group of miRNAs is consistently altered in neurodegenerative disorders, with effect size and direction of effect being tissue and disease-stage specific. miRNA profiling may, in the future, help with disease classification and diagnosis for several reasons. Firstly, because our signature allows us to clearly distinguish sCJD from AD using whole blood: the decrease in hsa-let-7i-5p, hsa-miR-16-5p and hsa-miR-93-5p in sCJD blood contrasts markedly with their upregulation in AD blood (Fig.2a and 3), and also AD serum, CSF and brain tissue[31,32,40]. Secondly, because the profiles of dysregulated miRNAs are highly variable between disease stages and disease models. Kanata *et al* recently conducted a comprehensive review of changes in miRNAs reported in mouse and primate models of prion disease[20]. The authors pointed out that the variability in direction of effects reported could be caused by the wide variety of models studied, technologies used and tissues analyzed (e.g. post mortem brain versus whole blood from living patients), as well as disease state (pre-clinical and clinical)[35,36,41]. Consistent with this, the sCJD miRNA signature we identified here is also found in sporadic ALS when the same tissue is analyzed[18]. There are significant parallels between the two conditions in terms of pathology associated with deposits of aggregated misfolded protein, and heterogeneous clinical phenotypes[42-44]. The finding that dysregulated miRNAs are shared between these two diseases suggests that common mechanisms might be involved, but does not negate any potential diagnostic relevance of the sCJD signature, since the two diseases are clinically very different (ALS is predominantly a disorder of motor neurons, whilst sCJD presents with pervasive brain dysfunction). Also of note is the study from Llorens *et al*, whose findings demonstrated widespread dysregulation of miRNA levels in several brain regions affected by sCJD and implicated the miRNA biosynthesis pathway in sCJD pathogenesis[36].

Insights into molecular mechanisms that can contribute to the disease process may also be provided by investigation of transcripts known to be targeted by the sCJD signature: the increased expression of several hsa-let-7i-5p, hsa-miR-16-5p and hsa-miR-93-5p target genes (Fig.2b) demonstrates that the observed downregulation in these three miRNAs in sCJD patients has concomitant effects on target gene regulation. By performing analysis of DE miRNA target binding sequences, we excluded the possibility that the observed downregulation in miRNAs resulted from Target RNA-Directed MicroRNA Degradation (TDMD)[45]. Intriguingly *ZFP36* (in protein form known as tristetraprolin, TTP), which was the most highly overexpressed target gene we tested in sCJD compared with controls (Fig.2b), is a stress granule associated RNA binding protein which has been linked with AD pathology in mice and humans[46,47]. Gene set enrichment analysis suggested that all six targets are associated with brain regions, which supports this being a peripheral signature of sCJD (Supplementary Table 3).

A major strength of this study was our ability to access longitudinal samples for 15 sCJD patients, which enabled us to test for association with disease progression. Whilst absolute expression levels of the signature did not associate with disease severity, we identified a positive correlation between rate of decline of expression and rate of disease progression (Fig.4a-d and Supplementary Fig.5a-d and 6a-d). Whether these miRNAs are a driver or passenger of speed of decline in sCJD remains to be established. Although the use of patient samples is desirable, it does however pose multiple caveats and limitations: confounding factors associated with disease status such as sample handling and storage prior to extraction, RNA degradation, age, environmental exposure and interactions with drugs could lead to changes in miRNA expression profiles. We addressed concerns about RNA degradation by conducting further analyses of the discovery cohort data to show that RIN did not have an impact on our findings (Supplementary Table 2). This is not surprising, as miRNA is known to be highly resistant to degradation in comparison to mRNA, and therefore RIN does not reflect the degradation status of miRNA[21]. Sequencing coverage in the discovery study is not high, but as we failed to validate hsa-miR-106b-3p by qPCR due to low expression, inclusion of DE miRNAs expressed at lower levels by resequencing would have been unlikely to yield additional DE miRNAs that could be validated by qPCR.

Our work was conducted in whole blood which has the advantage of being an accessible tissue, which therefore enabled us to study a large group of patients from early disease stages, and longitudinally. It will be important to establish whether the findings reported here are replicated in other tissues and body fluids such as CSF and brain tissue in order to determine whether the miRNA signature we have identified in blood is present in the brain, with potential additional effects on brain specific mRNA targets. Other future analyses might consider the impact of sex, ethnicity, co-morbidities, subtypes of disease and specific symptoms on the miRNA profile. In conclusion, our analysis of a large cohort of sCJD patients and controls has revealed, for the first time, that sCJD affects miRNA expression profiles in peripheral blood, and additionally has identified a miRNA signature whose rate of decline in expression is an indicator of disease progression. These findings provide the basis for a better mechanistic understanding of sCJD and represent an opportunity to open much needed new avenues for improved disease diagnosis, and therapeutic intervention.

Methods

Participants

Patients with a definite or probable diagnosis of sCJD according to World Health Organization criteria were recruited by the National Prion Clinic (London, UK). sCJD patients in the longitudinal cohort were participants in the UK National Prion Monitoring Cohort[48]. MRC Prion Disease Rating Scale scores (on a scale of 0-20, where 20 is unaffected) were derived for patients in the longitudinal cohort as previously described[48], and rates of decline (% loss of function per day) calculated according to the linear mixed model method described in Mead *et al*[4].

Healthy control donors were recruited from spouses or relatives of patients by the National Prion Clinic (London, UK), and the UCL Dementia Research Centre (London, UK). Patients diagnosed with AD according to International Working Group-2 criteria[49] were recruited by the UCL Dementia Research Centre (London, UK) and other referrers in the UK from 2012-2018. The study was approved by the London – Harrow Research Ethics Committee (reference 05/Q0505/113). Samples were obtained with written informed consent from controls, patients, or a patient's consultee in accordance with applicable UK legislation and Codes of Practice.

Sample collection and RNA extraction

Whole blood from patients and controls was collected into PAXgene tubes (PreAnalytiX, Hombrechtikon, Switzerland) and stored at -80°C prior to RNA extraction. Total RNA was extracted from 1ml whole blood using the Preserved Blood RNA Purification Kit II (Norgen Biotek, Thorold, Canada) followed by DNAse I digestion and concentration using RNA Clean & Concentrator-5 columns (Zymo Research, Irvine, US) according to manufacturer's instructions. All RNA samples were subsequently run on a TapeStation 2200 (Agilent, Santa Clara, US) using High Sensitivity RNA ScreenTapes. RNA samples with RNA integrity number (RIN) <2.5 were excluded from the study.

Small RNA library preparation, sequencing and analysis

Small RNA libraries were prepared using the TruSeq Small RNA Library Prep Kit (Illumina, San Diego, US) according to the manufacturer's instructions up to and including the PCR Amplification step. Size selection was then carried out using the PippinPrep size selection system (Sage Science, Beverly, US) with 2% dye free agarose gel cassettes with Marker L, run using the program for 3% DF Marker F gel cassette. The upper and lower size selection thresholds were 137 and 200 bp respectively. The eluted size fractions were concentrated using DNA Clean and Concentrator-5 columns (Zymo Research, Irvine, US). Successful library preparation and size selection was confirmed using High Sensitivity D1000 ScreenTapes and the TapeStation 2200 (both Agilent, Santa Clara, US). Libraries were normalised to 2nM using 10mM Tris-HCL, pH8.5 and 12 libraries were pooled by combining equal volumes of each library. Illumina's pooling guidelines were followed regarding index combinations. Pooled libraries were single end sequenced (120 cycles) with the MiSeq Reagent Kit v3 on a MiSeq sequencer (Illumina, San Diego, US) located in the University College London Genomics Laboratory (UCL Genomics) at the Institute of Child Health, London UK according to the manufacturer's instructions. PhiX DNA was added to pooled libraries prior to sequencing to give a final concentration of 5% in order to increase the sequence diversity of the libraries.

Each MiSeq run was subjected to quality control (QC): successful runs were considered to have passed QC if the percentage of clusters passing filter, and average percentage of bases with Quality (Q) score >30/40 both exceeded 80%, and cluster density >800K/mm^2 with even pooling. FastQ files

from all MiSeq runs passing QC were downloaded from BaseSpace (Illumina, San Diego, US) and uploaded into Partek Flow (Partek Inc, St. Louis, US), along with metadata. Samples yielding less than one million reads were excluded. Adapter sequences were removed and reads trimmed to a minimum length of 15bp with a minimum quality score of 25. Reads were aligned to the human genome (hg38) using Bowtie 2 v2.2.5 with a seed length of 10 with 1 mismatch, quantified for annotated miRNAs (miRBase v21) and normalized using Cufflinks v2.2.1 default settings. Gene Specific Analysis (GSA) was carried out using a proxy for sample age, and sampling age as covariates determined by post-normalization Principal Component Analysis (PCA), and a lowest average coverage filter of 5000 determined using a shrinkage plot.

Relative quantification of miRNAs by reverse transcription quantitative PCR (RT-qPCR)

Power calculations based on the outcome of the small RNA-seq study determined that n=30 for both patient and control groups would be required for replication of results in an independent sample set. To this end, 10ng total RNA from all samples was reverse transcribed using the miScript II RT Kit (Qiagen, Hilden, Germany) followed by qPCR carried out using the miScript SYBR Green PCR Kit and miScript Primer assays (both Qiagen, Hilden, Germany) according to the manufacturer's instructions. MiScript PCR Controls RNU6-2, SNORD42B, SNORD72 and SNORD95 were used as endogenous controls, and all samples were run in duplicate on a QuantStudio 12K Flex (Life Technologies, Carlsbad, US) with dissociation curves to check for specific amplification. Data was analyzed using the ΔCt method to generate ratios of expression of test miRNA compared to endogenous controls, and the $\Delta\Delta$Ct method to generate fold changes between patient and control groups.

miRNA target identification and expression

Target genes for hsa-miR-16-5p, hsa-miR-93-5p and hsa-let-7i-5p were selected using TarBase v8 from DIANA tools[50]. Genes validated by luciferase assay were prioritized. Where no luciferase data was available (hsa-let-7i-5p), targets validated by immunoprecipitation in >5 publications were selected. Shortlisted targets for each miRNA with the highest level of expression in whole blood (GTEx, https://gtexportal.org/home/)[51] were then selected for expression analysis in the replication cohort.

cDNA preparation and qPCR analysis were performed as previously described[52]. Each experiment was performed in at least two technical replicates on a QuantStudio 12K Flex. Primers were purchased from Qiagen for *CCND3* (hsa-miR-16-5p target), *VEGFA* (hsa-miR-16-5p and hsa-miR-93-5p target), *CDKN1A* (hsa-miR-93-5p target), *ZFP36, NAP1L1* and *RNF44* (hsa-let-7i-5p targets), *B2M, ALAS1* and *ACTB* (endogenous controls), and *MCM7*. Qiagen primer reference numbers were as follows: *CCND3* QT00096796; *VEGFA* QT01010184; *CDKN1A* QT00062090; *ZFP36* QT00091357; *NAP1L1* QT00085635; *RNF44* QT00051793; *MCM7* QT00053228; *ACTB* QT01680476; *B2M* QT00088935; *ALAS1* QT00073122. Gene set enrichment analysis was performed using the ENRICHR program (http://amp.pharm.mssm.edu/Enrichr/)[53,54].

Statistical Analysis

Small RNA-seq differential expression p values were adjusted for multiple testing using the Benjamini-Hochberg false discovery rate (FDR) method. miRNA expression data from the discovery cohort sCJD group was subjected to Pearson or Spearman correlation (as appropriate) with clinical parameters after first checking data for normality. Clinical parameters tested were age of onset, duration of disease, MRC Scale score and MRC Scale slope, and correlation p values were Bonferroni corrected for multiple testing. For miRNA and mRNA qPCR data, statistical comparisons between groups were carried out using Prism v5.03 (GraphPad, San Diego, US) by two–tailed Mann-Whitney test, or one-tailed Mann-Whitney test where there was prior knowledge of the direction of effect e.g. for qPCR replication of discovery cohort data. Longitudinal data was analyzed by linear regression using Prism.

References

1 Collinge, J. Prion diseases of humans and animals: their causes and molecular basis. *Annual review of neuroscience* **24**, 519-550, doi:10.1146/annurev.neuro.24.1.519 (2001).

2 Bolton, D. C., McKinley, M. P. & Prusiner, S. B. Identification of a protein that purifies with the scrapie prion. *Science* **218**, 1309-1311, doi:10.1126/science.6815801 (1982).

3 Terry, C. *et al.* Ex vivo mammalian prions are formed of paired double helical prion protein fibrils. *Open biology* **6**, doi:10.1098/rsob.160035 (2016).

4 Mead, S. *et al.* Clinical Trial Simulations Based on Genetic Stratification and the Natural History of a Functional Outcome Measure in Creutzfeldt-Jakob Disease. *JAMA neurology* **73**, 447-455, doi:10.1001/jamaneurol.2015.4885 (2016).

5 Windl, O. *et al.* Genetic basis of Creutzfeldt-Jakob disease in the United Kingdom: a systematic analysis of predisposing mutations and allelic variation in the PRNP gene. *Human genetics* **98**, 259-264, doi:10.1007/s004390050204 (1996).

6 Hill, A. F. *et al.* Molecular classification of sporadic Creutzfeldt-Jakob disease. *Brain : a journal of neurology* **126**, 1333-1346, doi:10.1093/brain/awg125 (2003).

7 Glatzel, M., Abela, E., Maissen, M. & Aguzzi, A. Extraneural pathologic prion protein in sporadic Creutzfeldt-Jakob disease. *The New England journal of medicine* **349**, 1812-1820, doi:10.1056/NEJMoa030351 (2003).

8 Head, M. W. *et al.* Abnormal prion protein in the retina of the most commonly occurring subtype of sporadic Creutzfeldt-Jakob disease. *The British journal of ophthalmology* **89**, 1131-1133, doi:10.1136/bjo.2004.063495 (2005).

9 Orru, C. D. *et al.* Prion Seeds Distribute throughout the Eyes of Sporadic Creutzfeldt-Jakob Disease Patients. *mBio* **9**, doi:10.1128/mBio.02095-18 (2018).

10 Orru, C. D. *et al.* Prion seeding activity and infectivity in skin samples from patients with sporadic Creutzfeldt-Jakob disease. *Science translational medicine* **9**, doi:10.1126/scitranslmed.aam7785 (2017).

11 He, L. & Hannon, G. J. MicroRNAs: small RNAs with a big role in gene regulation. *Nature reviews. Genetics* **5**, 522-531, doi:10.1038/nrg1379 (2004).

12 Rayner, K. J. & Hennessy, E. J. Extracellular communication via microRNA: lipid particles have a new message. *Journal of lipid research* **54**, 1174-1181, doi:10.1194/jlr.R034991 (2013).

13 Correia, C. N. *et al.* Circulating microRNAs as Potential Biomarkers of Infectious Disease. *Frontiers in immunology* **8**, 118, doi:10.3389/fimmu.2017.00118 (2017).

14 Kai, K., Dittmar, R. L. & Sen, S. Secretory microRNAs as biomarkers of cancer. *Seminars in cell & developmental biology* **78**, 22-36, doi:10.1016/j.semcdb.2017.12.011 (2018).

15 Viswambharan, V., Thanseem, I., Vasu, M. M., Poovathinal, S. A. & Anitha, A. miRNAs as biomarkers of neurodegenerative disorders. *Biomarkers in medicine* **11**, 151-167, doi:10.2217/bmm-2016-0242 (2017).

16 Abe, M. & Bonini, N. M. MicroRNAs and neurodegeneration: role and impact. *Trends in cell biology* **23**, 30-36, doi:10.1016/j.tcb.2012.08.013 (2013).

17 Hebert, S. S. & De Strooper, B. Alterations of the microRNA network cause neurodegenerative disease. *Trends in neurosciences* **32**, 199-206, doi:10.1016/j.tins.2008.12.003 (2009).

18 Liguori, M. *et al.* Dysregulation of MicroRNAs and Target Genes Networks in Peripheral Blood of Patients With Sporadic Amyotrophic Lateral Sclerosis. *Frontiers in molecular neuroscience* **11**, 288, doi:10.3389/fnmol.2018.00288 (2018).

19 Tan, L., Yu, J. T. & Tan, L. Causes and Consequences of MicroRNA Dysregulation in Neurodegenerative Diseases. *Molecular neurobiology* **51**, 1249-1262, doi:10.1007/s12035-014-8803-9 (2015).

20 Kanata, E. *et al.* MicroRNA Alterations in the Brain and Body Fluids of Humans and Animal Prion Disease Models: Current Status and Perspectives. *Frontiers in aging neuroscience* **10**, 220, doi:10.3389/fnagi.2018.00220 (2018).

21 Jung, M. *et al.* Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. *Clinical chemistry* **56**, 998-1006, doi:10.1373/clinchem.2009.141580 (2010).

22 Giovanni, A. *et al.* E2F1 mediates death of B-amyloid-treated cortical neurons in a manner independent of p53 and dependent on Bax and caspase 3. *The Journal of biological chemistry* **275**, 11553-11560, doi:10.1074/jbc.275.16.11553 (2000).

23 Hoglinger, G. U. *et al.* The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease. *Proceedings of the National Academy of Sciences of the United States of America* **104**, 3585-3590, doi:10.1073/pnas.0611671104 (2007).

24 Ranganathan, S. & Bowser, R. Alterations in G(1) to S phase cell-cycle regulators during amyotrophic lateral sclerosis. *The American journal of pathology* **162**, 823-835, doi:10.1016/S0002-9440(10)63879-5 (2003).

25 Gupta, S. *et al.* Perk-dependent repression of miR-106b-25 cluster is required for ER stress-induced apoptosis. *Cell death & disease* **3**, e333, doi:10.1038/cddis.2012.74 (2012).

26 Stefani, I. C., Wright, D., Polizzi, K. M. & Kontoravdi, C. The role of ER stress-induced apoptosis in neurodegeneration. *Current Alzheimer research* **9**, 373-387 (2012).

27 Dong, H. *et al.* Serum MicroRNA Profiles Serve as Novel Biomarkers for the Diagnosis of Alzheimer's Disease. *Disease markers* **2015**, 625659, doi:10.1155/2015/625659 (2015).

28 Balakrishnan, I. *et al.* Genome-wide analysis of miRNA-mRNA interactions in marrow stromal cells. *Stem cells* **32**, 662-673, doi:10.1002/stem.1531 (2014).

29 Boudreau, R. L. *et al.* Transcriptome-wide discovery of microRNA binding sites in human brain. *Neuron* **81**, 294-305, doi:10.1016/j.neuron.2013.10.062 (2014).

30 Kishore, S. *et al.* A quantitative analysis of CLIP methods for identifying binding sites of RNA-binding proteins. *Nature methods* **8**, 559-564, doi:10.1038/nmeth.1608 (2011).

31 Lau, P. *et al.* Alteration of the microRNA network during the progression of Alzheimer's disease. *EMBO molecular medicine* **5**, 1613-1634, doi:10.1002/emmm.201201974 (2013).

32 Sorensen, S. S., Nygaard, A. B. & Christensen, T. miRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer's disease and other types of dementia - an exploratory study. *Translational neurodegeneration* **5**, 6, doi:10.1186/s40035-016-0053-5 (2016).

33 Bellingham, S. A., Coleman, B. M. & Hill, A. F. Small RNA deep sequencing reveals a distinct miRNA signature released in exosomes from prion-infected neuronal cells. *Nucleic acids research* **40**, 10937-10949, doi:10.1093/nar/gks832 (2012).

34 Burak, K. *et al.* MicroRNA-16 targets mRNA involved in neurite extension and branching in hippocampal neurons during presymptomatic prion disease. *Neurobiology of disease* **112**, 1-13, doi:10.1016/j.nbd.2017.12.011 (2018).

35 Majer, A. *et al.* Early mechanisms of pathobiology are revealed by transcriptional temporal dynamics in hippocampal CA1 neurons of prion infected mice. *PLoS pathogens* **8**, e1003002, doi:10.1371/journal.ppat.1003002 (2012).

36 Llorens, F. *et al.* Regional and subtype-dependent miRNA signatures in sporadic Creutzfeldt-Jakob disease are accompanied by alterations in miRNA silencing machinery and biogenesis. *PLoS pathogens* **14**, e1006802, doi:10.1371/journal.ppat.1006802 (2018).

37 Hebert, S. S., Sergeant, N. & Buee, L. MicroRNAs and the Regulation of Tau Metabolism. *International journal of Alzheimer's disease* **2012**, 406561, doi:10.1155/2012/406561 (2012).

38 Liu, W. *et al.* MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer's-associated pathogenesis in SAMP8 mice. *Neurobiology of aging* **33**, 522-534, doi:10.1016/j.neurobiolaging.2010.04.034 (2012).

39 McKeever, P. M. *et al.* MicroRNA Expression Levels Are Altered in the Cerebrospinal Fluid of Patients with Young-Onset Alzheimer's Disease. *Molecular neurobiology* **55**, 8826-8841, doi:10.1007/s12035-018-1032-x (2018).

40 Cheng, L. *et al.* Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment. *Molecular psychiatry* **20**, 1188-1196, doi:10.1038/mp.2014.127 (2015).

41 Boese, A. S. *et al.* MicroRNA abundance is altered in synaptoneurosomes during prion disease. *Molecular and cellular neurosciences* **71**, 13-24, doi:10.1016/j.mcn.2015.12.001 (2016).

42 Polymenidou, M. & Cleveland, D. W. The seeds of neurodegeneration: prion-like spreading in ALS. *Cell* **147**, 498-508, doi:10.1016/j.cell.2011.10.011 (2011).

43 Smethurst, P. *et al.* In vitro prion-like behaviour of TDP-43 in ALS. *Neurobiology of disease* **96**, 236-247, doi:10.1016/j.nbd.2016.08.007 (2016).

44 Smethurst, P., Sidle, K. C. & Hardy, J. Review: Prion-like mechanisms of transactive response DNA binding protein of 43 kDa (TDP-43) in amyotrophic lateral sclerosis (ALS). *Neuropathology and applied neurobiology* **41**, 578-597, doi:10.1111/nan.12206 (2015).

45 Fuchs Wightman, F., Giono, L. E., Fededa, J. P. & de la Mata, M. Target RNAs Strike Back on MicroRNAs. *Frontiers in genetics* **9**, 435, doi:10.3389/fgene.2018.00435 (2018).

46 Ash, P. E., Vanderweyde, T. E., Youmans, K. L., Apicco, D. J. & Wolozin, B. Pathological stress granules in Alzheimer's disease. *Brain research* **1584**, 52-58, doi:10.1016/j.brainres.2014.05.052 (2014).

47 Vanderweyde, T. *et al.* Contrasting pathology of the stress granule proteins TIA-1 and G3BP in tauopathies. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **32**, 8270-8283, doi:10.1523/JNEUROSCI.1592-12.2012 (2012).

48 Thompson, A. G. *et al.* The Medical Research Council prion disease rating scale: a new outcome measure for prion disease therapeutic trials developed and validated using

systematic observational studies. *Brain : a journal of neurology* **136**, 1116-1127, doi:10.1093/brain/awt048 (2013).

49 Dubois, B. *et al.* Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. *The Lancet. Neurology* **13**, 614-629, doi:10.1016/S1474-4422(14)70090-0 (2014).

50 Karagkouni, D. *et al.* DIANA-TarBase v8: a decade-long collection of experimentally supported miRNA-gene interactions. *Nucleic acids research* **46**, D239-D245, doi:10.1093/nar/gkx1141 (2018).

51 Consortium, G. T. The Genotype-Tissue Expression (GTEx) project. *Nature genetics* **45**, 580-585, doi:10.1038/ng.2653 (2013).

52 Vire, E. *et al.* The Breast Cancer Oncogene EMSY Represses Transcription of Antimetastatic microRNA miR-31. *Molecular cell* **54**, 203, doi:10.1016/j.molcel.2014.03.041 (2014).

53 Chen, E. Y. *et al.* Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC bioinformatics* **14**, 128, doi:10.1186/1471-2105-14-128 (2013).

54 Kuleshov, M. V. *et al.* Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic acids research* **44**, W90-97, doi:10.1093/nar/gkw377 (2016).

Acknowledgements: We are very grateful to patients and volunteers who have made this study possible by donating blood samples and their time to research; Holger Hummerich for helpful discussions; Tony Brooks, Paola Niola, and Mark Kristiansen from UCL Genomics for technical assistance with MiSeq; Tracy Campbell, Fernando Guntoro, Joanna Field and Akin Nihat for help with metadata acquisition.

Author Contributions: S.M. had full access to all data in the study and takes responsibility for integrity of the data and accuracy of the data analysis. All authors read and approved the final manuscript. Concept and design: E.A.V, S.M; Acquisition, analysis, or interpretation of data: All authors; Drafting of manuscript: P.J.N, E.A.V, S.M; Statistical analysis: P.J.N; Obtaining funding: J.C, S.M; Administrative, technical, or material support: P.J.N, E.A.V, S.M, J.C; Study supervision: S.M, E.A.V.

Conflict of Interest Disclosures: Prof. Collinge is a director and shareholder of D-Gen Limited (London), an academic spinout company working in the field of prion disease diagnosis, decontamination, and therapeutics. Prof. Schott has received research funding and PET tracer from AVID Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly); has consulted for Roche, Eli Lilly, Biogen and Merck, GE; received royalties from Oxford University Press and Henry Stewart Talks; given education lectures sponsored by Eli Lilly, Biogen and GE; and serves on a Data Safety Monitoring Committee for Axon Neuroscience SE. No other disclosures were reported.

Funding/Support: This study was funded by the UK Medical Research Council and the National Institute of Health Research (NIHR) Biomedical Research Centre at UCL Hospitals NHS Foundation Trust. SM and JC are NIHR Senior Investigators. JMS is supported by the NIHR University College London Hospitals Biomedical Research Centre, Wolfson Foundation, Engineering and Physical Sciences Research Council, MRC Dementias Platform UK, Alzheimer's Research UK (ARUK), Brain Research UK, Weston Brain Institute and European Union's Horizon 2020 research and innovation programme. RWP is funded by an NIHR clinical lectureship, AGBT was funded by clinical lectureships from NIHR and ARUK, and THM is funded by a clinical research fellowship from the Alzheimer's Society.

Role of the Funder/Sponsor: The sponsor provided financial support for the research but was not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Materials and Correspondence: Correspondence and material requests to be addressed to S.M.

Figure legends

Fig.1 Differential expression of miRNAs in the discovery cohort measured by small RNA-seq

Volcano plot (a): miRNAs with differential expression >1.5 fold change are delineated with vertical lines, and those with significant differential expression with adjusted $p<0.05$ are delineated by a horizontal line. Expression of DE miRNAs (b), plotted by normalised transcript count (in Fragments

Per Kilobase of transcript per Million mapped reads, FPKM) with median and interquartile range are shown for both control and sCJD groups. *p<0.05, **p<0.01, ***p<0.001. Hierarchical clustering of DE miRNA profiles (c), illustrating relationships between both DE miRNAs, and individuals within the discovery cohort.

Fig.2 Validation and replication of DE miRNAs, and expression of target mRNAs measured by qRT-PCR

Expression of DE miRNAs (a), relative to the control small RNA RNU6-2 with median and interquartile range, are shown for both control and sCJD groups. Fold change (FC) as follows: hsa-let-7i-5p FC -1.82; hsa-miR-16-5p FC -1.87; hsa-miR-93-5p FC -1.74; hsa-let-7d-3p FC 1.14; hsa-miR-484 FC 1.09; *p<0.05. Expression of target mRNAs (b), plotted relative to combined expression of control mRNAs (*ALAS1*, *B2M* and *ACTB*) in control and sCJD groups. Median and range are shown. Median FC as follows: *CCND3* FC 1.39; *VEGFA* FC 1.02; *CDKN1A* FC1.41; *ZFP36* FC 2.21; *NAPL1L* FC 1.67; *RNF44* FC -1.43. *p <0.05

Fig.3 Expression of replicated DE miRNAs in Alzheimer's Disease (AD) measured by qRT-PCR

Expression relative to the control RNA RNU6-2 with median and interquartile range are shown for control and AD groups. hsa-let-7i-5p FC 3.84; hsa-miR-16-5p FC 4.46; hsa-miR-93-5p FC 3.22. ***p<0.001

Fig.4 Relationship between disease progression and change in DE miRNA levels in longitudinal samples from sCJD patients

miRNA expression was measured relative to the control small RNA RNU6-2 for (a) hsa-let-7i-5p, (b) hsa-miR-16-5p, (c) hsa-miR-93-5p and (d) hsa-miR-484. hsa-miR-484 is a non-DE miRNA shown here for comparison. %Loss of function per day was calculated from decline in MRC Scale score. R^2 and p values are shown. Dotted lines represent 95% confidence intervals. Data points are coded by *PRNP* codon 129 genotype (MM blue triangle, MV magenta diamonds, VV green inverted triangle)

Table 1 Patient data by study group.

	Discovery Cohort		**Replication Cohort**		**AD Cohort**		**Longitudinal sCJD cohort**	
Group	sCJD	Control	sCJD	Control	AD	Control	No. samples/patient, median (IQR[a])	2 (2-3)
n	57	50	29	30	30	30	n	15
Female/Male, n (%)	31/26 (54/46)	30/20 (60/40)	12/17 (41/59)	13/17 (43/57)	12/18 (40/60)	13/17 (43/57)	Female/Male, n (%)	6/9 (40/60)
Sampling age, mean (SD[b]), yrs	66 (8)	53 (15)	63 (7)	59 (13)	61 (5)	59 (13)	Age at first sample, mean (SD), yrs	64 (8)
RIN[c], mean (SD)	5.6 (1.3)	6.5 (1.2)	5.8 (1.8)	6.8 (1.0)	6.6 (0.6)	6.8 (1.0)	RIN (all samples), mean (SD)	5.7 (1.2)
PRNP codon 129 genotype[d], n (%)	26/15/16 (46/26/28)	16/25/8 (33/51/16)	10/12/6 (36/43/21)	7/7/5 (37/37/26)	N/A	N/A	*PRNP* codon 129 genotype, n (%)	1/10/4 (7/66/27)
MRC Scale score[e,45], mean (SD)	6.86 (5.48)	20 (0)	7.89 (5.81)	20 (0)	N/A	N/A	MRC Scale slope[f,4], mean (SD)	0.335 (0.263)

[a]Interquartile Range; [b]Standard Deviation; [c]RNA Integrity Number; [d]In order MM/MV/VV, where numbers do not add up to group totals this is due to unavailability of a small number of samples; [e]MRC Prion Disease Rating Scale score, a measure of disease severity from 0-20, with 20 being unaffected; [f]Rate of disease progression measured in % reduction in function per day; N/A Parameter not relevant to AD.

Fig.1

a


p (adjusted)
Log2FoldChange

b


Normalised reads (FPKM)
let-7i-5p***
miR-16-5p**
miR-93-5p***
miR-106b-3p**
let-7d-3p*
Control
sCJD

c


Z-score
sCJD
Control
miR-106b-3p
miR-16-5p
miR-93-5p
let-7i-5p
let-7d-3p

Fig.2

a


3.2x10¹
1.0x10⁰
3.1x10⁻²
9.8x10⁻⁴
Relative expression
let-7i-5p*
miR-16-5p*
miR-93-5p*
let-7d-3p
miR-484
Control
sCJD

b


3
2
1
0
Relative expression
Control
sCJD
CCND3*
VEGFA
CDKN1A*
ZFP36*
NAP1L1*
RNF44

Fig.3


1.0x10³
3.2x10¹
1.0x10⁰
3.1x10⁻²
9.8x10⁻⁴
Relative expression
Let-7i-5p***
miR-16-5p***
miR-93-5p***
Control
AD

Fig.4


a
let-7i-5p
R^2 0.377
p=0.015
Change in relative expression per day
%Loss of function per day
b
miR-16-5p
R^2 0.353
p=0.019
Change in relative expression per day
%Loss of function per day
c
miR-93-5p
R^2 0.572
p=0.001
Change in relative expression per day
%Loss of function per day
d
miR-484
R^2 0.052
p=0.415
Change in relative expression per day
%Loss of function per day